General and Genetic Toxicology of Enzyme-Treated Ginseng Extract - Toxicology of Ginseng Rh2+ -
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: Ginseng Rh2+ is enzyme-treated ginseng extract containing high amounts of converted ginsenosides, such as compound k, Rh2, Rg3, which have potent anticancer activity. We conducted general and genetic toxicity tests to evaluate the safety of ginseng Rh2+. Methods: An acute oral toxicity test was performed at a high-level dose of 4,000 mg/kg/day in Sprague-Dawley (SD) rats. A 14-day range-finding study was also conducted to set dose levels for the 90-day study. A subchronic 90-day toxicity study was performed at dose levels of 1,000 and 2,000 mg/kg/day to investigate the no-observed-adverse-effect level (NOAEL) of ginseng Rh2+ and target organs. To identify the mutagenic potential of ginseng Rh2+, we conducted a bacterial reverse mutation test (Ames test) using amino-acid-requiring strains of Salmonella typhimurium and Escherichia coli (E. coli), a chromosome aberration test with Chinese hamster lung (CHL) cells, and an in vivo micronucleus test using ICR mice bone marrow as recommended by the Korean Ministry of Food and Drug Safety. Results: According to the results of the acute oral toxicity study, the approximate lethal dose (ALD) of ginseng Rh2+ was estimated to be higher than 4,000 mg/kg. For the 90-day study, no toxicological effect of ginseng Rh2+ was observed in body-weight changes, food consumption, clinical signs, organ weights, histopathology, ophthalmology, and clinical pathology. The NOAEL of ginseng Rh2+ was established to be 2,000 mg/kg/day, and no target organ was found in this test. In addition, no evidence of mutagenicity was found either on the in vitro genotoxicity tests, including the Ames test and the chromosome aberration test, or on the in vivo in mice bone marrow micronucleus test. Conclusion: On the basis of our findings, ginseng Rh2+ is a non-toxic material with no genotoxicity. We expect that ginseng Rh2+ may be used as a novel adjuvant anticancer agent that is safe for long-term administration.
Abstract
Objectives: Ginseng Rh2+ is enzyme-treated ginseng extract containing high amounts of converted ginsenosides, such as compound k, Rh2, Rg3, which have potent anticancer activity. We conducted general and genetic toxicity tests to evaluate the safety of ginseng Rh2+. Methods: An acute oral toxicity test was performed at a high-level dose of 4,000 mg/kg/day in Sprague-Dawley (SD) rats. A 14-day range-finding study was also conducted to set dose levels for the 90-day study. A subchronic 90-day toxicity study was performed at dose levels of 1,000 and 2,000 mg/kg/day to investigate the no-observed-adverse-effect level (NOAEL) of ginseng Rh2+ and target organs. To identify the mutagenic potential of ginseng Rh2+, we conducted a bacterial reverse mutation test (Ames test) using amino-acid-requiring strains of Salmonella typhimurium and Escherichia coli (E. coli), a chromosome aberration test with Chinese hamster lung (CHL) cells, and an in vivo micronucleus test using ICR mice bone marrow as recommended by the Korean Ministry of Food and Drug Safety. Results: According to the results of the acute oral toxicity study, the approximate lethal dose (ALD) of ginseng Rh2+ was estimated to be higher than 4,000 mg/kg. For the 90-day study, no toxicological effect of ginseng Rh2+ was observed in body-weight changes, food consumption, clinical signs, organ weights, histopathology, ophthalmology, and clinical pathology. The NOAEL of ginseng Rh2+ was established to be 2,000 mg/kg/day, and no target organ was found in this test. In addition, no evidence of mutagenicity was found either on the in vitro genotoxicity tests, including the Ames test and the chromosome aberration test, or on the in vivo in mice bone marrow micronucleus test. Conclusion: On the basis of our findings, ginseng Rh2+ is a non-toxic material with no genotoxicity. We expect that ginseng Rh2+ may be used as a novel adjuvant anticancer agent that is safe for long-term administration.
참고문헌 (41)
- Jia L, "Current evaluation of the millennium phytomedicine--ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations", Curr Med Chem, 16(19), pp.2475~2484 (2009)
- Christensen LP, "Ginsenosides chemistry, biosynthesis, analysis, and potential health effects", Adv Food Nutr Res, 55, pp.1~99 (2009)
- Qi LW, "Isolation and analysis of ginseng: advances and challenges", Nat Prod Rep, 28(3), pp.467~495 (2011)
- Byong-Kyu Shin, "Chemical diversity of ginseng saponins from Panax ginseng", Journal of Ginseng Research, 39(4), pp.287~298 (2015), 고려인삼학회
- Wang W, "In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng", Cancer Chemother Pharmacol, 59(5), pp.589~601 (2007)
- Wang CZ, "Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer", Int J Oncol, 40(6), pp.1970~1976 (2012)
- Shibata S, "Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds", J Korean Med Sci, S16, pp.S28~S37 (2001)
- Jang SI, "Identification of target genes involved in the antiproliferative effect of enzyme-modified ginseng extract in HepG2 hepatocarcinoma cell", Evid Based Complement Alternat Med, 2013 (2013)
- Kim KH, "Target genes involved in antiproliferative effect of modified ginseng extracts in lung cancer A549 cells", Acta Biochim Biophys Sin (Shanghai), 46(6), pp.441~449 (2014)
- Hwang JW, "An enzymatically fortified ginseng extract inhibits proliferation and induces apoptosis of KATO3 human gastric cancer cells via modulation of Bax, mTOR, PKB and IκBα", Mol Med Rep, 11(1), pp.670~676 (2015)
- Chan PC, "Two-year toxicity and carcinogenicity studies of Panax ginseng in fischer 344 rats and B6C3F1 mice", Am J Chin Med, 39(4), pp.779~788 (2011)
- Seely D, "Safety and efficacy of Panax ginseng during pregnancy and lactation", Can J Clin Pharmacol, 15(1), pp.e87~e94 (2008)
- 박상진, "Subacute Oral Toxicity Study of Korean Red Ginseng Extract in Sprague-Dawley Rats", 한국독성학회지, 29(4), pp.285~292 (2013), 한국독성학회[DOI]
- Schmid W, "The micronucleus test", Mutat Res, 31(1), pp.9~15 (1975)
- Tawab MA, "Degradation of ginsenosides in humans after oral administration", Drug Metab Dispos, 31(8), pp.1065~1071 (2003)
- Hasegawa H, "Proof of the mysterious efficacy of ginseng : basic and clinical trials : metabolic activation of ginsenoside : deglycosylation by intestinal bacteria and esterification with fatty acid", J Pharmacol Sci, 95(2), pp.153~157 (2004)
- So Jin Lee, "Changes in the ginsenoside content during the fermentation process using microbial strains", Journal of Ginseng Research, 39(4), pp.392~397 (2015), 고려인삼학회
- Quan LH, "Microbial transformation of ginsenoside Rb1 to compound K by Lactobacillus paralimentarius", World J Microbiol Biotechnol, 29(6), pp.1001~1007 (2013)
- Cho SH, "Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells", BMC Cancer, 9, pp.449~ (2009)
- Zheng ZZ, "Compound K-induced apoptosis of human hepatocellular carcinoma MHCC97-H cells in vitro", Oncol Rep, 32(1), pp.325~331 (2014)
- Kim AD, "A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells", Cell Death Dis, 4, pp.e750~ (2013)
- Hu C, "Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by augmenting apoptosis via Bid-mediated mitochondrial pathway", J Cell Mol Med, 16(1), pp.96~106 (2012)
- Kang KA, "Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity", Int J Oncol, 43(6), pp.1907~1914 (2013)
- Zhang Z, "Compound K, a ginsenoside metabolite, inhibits colon cancer growth via multiple pathways including p53-p21 interactions", Int J Mol Sci, 14(2), pp.2980~2995 (2013)
- Wang CZ, "Ginseng metabolites on cancer chemoprevention: an angiogenesis link", Diseases, 3(3), pp.193~204 (2015)
- Yang Z, "Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy", Sci Rep, 6, pp.19383~ (2016)
- Tang XP, "Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells", World J Gastroenterol, 19(10), pp.1582~1592 (2013)
- Choi S, "Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases", Pharm Res, 26(10), pp.2280~2288 (2009)
- Yoon JH, "Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells", Eur J Pharmacol, 679(1-3), pp.24~33 (2012)
- Jung JS, "Protopanaxatriol ginsenoside Rh1 inhibits the expression of matrix metalloproteinases and the in vitro invasion", migration of human astroglioma cells, 2013, pp.63(2), 80~86
- "Test No. 471: Bacterial Reverse Mutation Test" (1997)[URL]
- Chen Q, "Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells", Food Chem Toxicol, 47(2), pp.328~334 (2009)
- Scheutwinkel-Reich M, "Sister-chromatid exchange in Chinese hamster V79 cells exposed to quindoxin, carbadox and olaquindox", Mutat Res, 139(4), pp.199~202 (1984)
- "Test No. 408: Repeated Dose 90-day Oral Toxicity Study in Rodents" (1998)[URL]
- Jena GB, "Genotoxicity testing, a regulatory requirement for drug discovery and development: impact of ICH guidelines", Indian J Pharm, 34, pp.86~99 (2002)
- Hesketh PJ, "Chemotherapy-induced nausea and vomiting", N Engl J Med, 358(23), pp.2482~2494 (2008)
- Shumay DM, "Why some cancer patients choose complementary and alternative medicine instead of conventional treatment", J Fam Pract, 50(12), pp.1067~ (2001)
- Tian JH, "A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients", Am J Chin Med, 38(1), pp.15~25 (2010)
- Wang CZ, "Herbal medicines as adjuvants for cancer therapeutics", Am J Chin Med, 40(4), pp.657~669 (2012)
- Li Y, "Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells", J Thorac Dis, 7(3), pp.400~406 (2015)
- Zhang K, "Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer", Pharm Biol, 54(4), pp.561~568 (2016)